Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association

被引:25
|
作者
Palsgrove, Doreen N. [1 ,2 ]
Brosnan-Cashman, Jacqueline A. [1 ]
Giannini, Caterina [3 ]
Raghunathan, Aditya [3 ]
Jentoft, Mark [4 ]
Bettegowda, Chetan [2 ,5 ]
Gokden, Murat [6 ]
Lin, Doris [7 ]
Yuan, Ming [1 ]
Lin, Ming-Tseh [1 ,2 ]
Heaphy, Christopher M. [1 ,2 ]
Rodriguez, Fausto J. [1 ,2 ]
机构
[1] Sidney Kimmel Comprehens Canc Ctr, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[4] Mayo Clin, Jacksonville, FL 32224 USA
[5] Sidney Kimmel Comprehens Canc Ctr, Dept Neurosurg, Baltimore, MD USA
[6] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
[7] Sidney Kimmel Comprehens Canc Ctr, Dept Radiol, Baltimore, MD USA
关键词
HISTONE CHAPERONE; TELOMERES; ATRX; RECQL4; INACTIVATION; INSTABILITY; PREVALENCE; MECHANISM; SARCOMAS; DIFFUSE;
D O I
10.1038/s41379-018-0103-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Neurofibromatosis type-1 is a familial genetic syndrome associated with a predisposition to develop peripheral and central nervous system neoplasms. We have previously reported on a subset of gliomas developing in these patients with morphologic features resembling subependymal giant cell astrocytoma, but the molecular features of these tumors remain undefined. A total of 14 tumors were studied and all available slides were reviewed. Immunohistochemical stains and telomere-specific FISH were performed on all cases. In addition, next-generation sequencing was performed on 11 cases using a platform targeting 644 cancer-related genes. The average age at diagnosis was 28 years (range: 4-60, 9F/5M). All tumors involved the supratentorial compartment. Tumors were predominantly low grade (n = 12), with two high-grade tumors, and displayed consistent expression of glial markers. Next-generation sequencing demonstrated inactivating NF1 mutations in 10 (of 11) cases. Concurrent TSC2 and RPTOR mutations were present in two cases (1 sporadic and 1 neurofibromatosis type-1-associated). Interestingly, alternative lengthening of telomeres was present in 4 (of 14) (29%) cases. However, an ATRX mutation associated with aberrant nuclear ATRX expression was identified in only one (of four) cases with alternative lenghtening of telomeres. Gene variants in the DNA helicase RECQL4 (n = 2) and components of the Fanconi anemia complementation group (FANCD2, FANCF, FANCG) (n = 1) were identified in two alternative lenghtening of telomere-positive/ATRX-intact cases. Other variants involved genes related to NOTCH signaling, DNA maintenance/repair pathways, and epigenetic modulators. There were no mutations identified in DAXX, PTEN, PIK3C genes, TP53, H3F3A, HIST1H3B, or in canonical hotspots of IDH1, IDH2, or BRAF. A subset of subependymal giant cell astrocytoma-like astrocytomas are alternative lenghtening of telomere-positive and occur in the absence of ATRX alterations, thereby suggesting mutations in other DNA repair/maintenance genes may also facilitate alternative lenghtening of telomeres. These findings suggest that subependymal giant cell astrocytoma-like astrocytoma represents a biologically distinct group that merits further investigation.
引用
收藏
页码:1787 / 1800
页数:14
相关论文
共 39 条
  • [21] Safety of Everolimus by Age Category for Subependymal Giant Cell Astrocytoma (SEGA) Associated with Tuberous Sclerosis Complex (TSC): results from the EXIST-1 trial
    Franz, D. N.
    Brechenmacher, T.
    Segal, S.
    Jozwiak, S.
    ANNALS OF NEUROLOGY, 2014, 76 : S179 - S179
  • [22] Secondary parathyroid hyperplasia in tuberous sclerosis - Report of a case with large eosinophilic ganglion-like cells similar to those of subependymal giant cell astrocytoma, tubers, and atypical angiomyolipoma
    Martin, HL
    Lee, E
    Albores-Saavedra, J
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (02) : 260 - 265
  • [23] Association between age, gender, residential region, and prevalence of subependymal giant cell astrocytoma among patients with tuberous sclerosis complex: A US Healthcare Claims Database study.
    Kohrman, Michael
    Sun, Peter
    Liu, Zhimei
    Kruger, Darcy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Everolimus for Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex: Final 4-year Long-Term Results from EXIST-1
    Franz, David N.
    Belousova, Elena
    Sparagana, Steven
    Bebin, E. M.
    Frost, Michael
    Kuperman, Rachel
    Witt, Olaf
    Kohrman, Michael H.
    Flamini, J. R.
    Wu, Joyce Y.
    Curatolo, Paolo
    De Vries, Petrus J.
    Berkowitz, Noah
    Niolat, Julie
    Jozwiak, Sergiusz
    ANNALS OF NEUROLOGY, 2015, 78 : S70 - S71
  • [25] Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
    Franz, David Neal
    Belousova, Elena
    Sparagana, Steven
    Bebin, E. Martina
    Frost, Michael
    Kuperman, Rachel
    Witt, Olaf
    Kohrman, Michael H.
    Flamini, J. Robert
    Wu, Joyce Y.
    Curatolo, Paolo
    de Vries, Petrus J.
    Berkowitz, Noah
    Anak, Oezlem
    Niolat, Julie
    Jozwiak, Sergiusz
    LANCET ONCOLOGY, 2014, 15 (13): : 1513 - 1520
  • [26] Thyroid transcription factor-1 distinguishes subependymal giant cell astrocytoma from its mimics and supports its cell origin from the progenitor cells in the medial ganglionic eminence
    Hang, Jen-Fan
    Hsu, Chih-Yi
    Lin, Shih-Chieh
    Wu, Chih-Chun
    Lee, Han-Jui
    Ho, Donald Ming-Tak
    MODERN PATHOLOGY, 2017, 30 (03) : 318 - 328
  • [27] Exploratory Analyses from the EXIST-1 Trial: The Effect of the mTOR Inhibitor Everolimus on Subependymal Nodule (SEN) and Tuber Volume in Patients with Subependymal Giant Cell Astrocytoma (SEGA) Associated with Tuberous Sclerosis Complex (TSC)
    Franz, D. N.
    Prestifilippo, J.
    Cauwel, H.
    Jozwiak, S.
    ANNALS OF NEUROLOGY, 2013, 74 : S135 - S135
  • [28] Everolimus for Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex: Final Long-Term Results from Approximately 4 Years of Treatment in EXIST-1
    Franz, D. N.
    Belousova, E.
    Sparagana, S.
    Bebin, E. M.
    Frost, M.
    Kuperman, R.
    Witt, O.
    Kohrman, M. H.
    Flamini, J. R.
    Wu, J. Y.
    Curatolo, P.
    de Vries, P. J.
    Berkowitz, N.
    Niolat, J.
    Jozwiak, S.
    ANNALS OF NEUROLOGY, 2015, 78 : S158 - S158
  • [29] EFFECT OF EVEROLIMUS THERAPY ON RENAL ANGIOMYOLIPOMA RESPONSE IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX BEING TREATED FOR SUBEPENDYMAL GIANT CELL ASTROCYTOMA: EXPLORATORY Results FROM EXIST-1
    Jansen, Anna
    Jozwiak, Sergiusz
    Belousova, Elena
    Frost, Michael
    Kuperman, Rachel
    Bebin, Martina
    Korf, Bruce
    Flamini, Robert
    Kohrman, Michael
    Sparagana, Steven
    Wu, Joyce
    Ford, James
    Shah, Gaurav
    Franz, David
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 325 - 325
  • [30] Identification of TSC1 or TSC2 mutation limited to the tumor in three cases of solitary subependymal giant cell astrocytoma using next-generation sequencing technology
    Fohlen, Martine
    Harzallah, Ines
    Polivka, Marc
    Giuliano, Fabienne
    Pons, Linda
    Streichenberger, Nathalie
    Dorfmueller, Georg
    Touraine, Renaud
    CHILDS NERVOUS SYSTEM, 2020, 36 (05) : 961 - 965